Hit enter to search or ESC to close

News

New Publication Demonstrates ATH434 is Neuroprotective

Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative conditions, today announced that Movement Disorders, the official journal of the International Parkinson and Movement Disorder Society, has published results from a study demonstrating that ATH434 reduces α‑synuclein related neurodegeneration in a widely accepted ...
Senior male researcher carrying out scientific research

Alterity Therapeutics granted a new US patent targeting major neurodegenerative diseases including Alzheimer’s and Parkinson’s

Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”) has today announced the granting of a new composition of matter patent by the United States Patent and Trademark Office (USPTO).  The patent secures a broad monopoly over a new class of iron chaperones, a technology capable of redistributing excess iron in the central nervous ...

European Union Regulatory Guidance for ATH434 Phase 2 Clinical Trial

Highlights: Alterity receives positive guidance from the European Medicines Agency’s Committee for Medicinal Products for Human Use on its Phase 2 clinical trial for Multiple System Atrophy. Concurrence with Alterity’s plan to target early stage MSA patients. Endorsement on selection of biomarker endpoints to assess pathological hallmarks of MSA. Agreement that ATH434 has potential as ...

Alterity Therapeutics to Present at the MST Access Australian Micro & Small Caps Conference

Alterity Therapeutics Limited (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to creating an alternate future for people living with neurodegenerative diseases, today announced that Dr David Stamler, Chief Executive Officer will present a company overview at the MST Access Australian Micro & Small Caps Conference on Thursday 17 June 2021 at ...

Quarterly Cash Flow Report

Highlights: Michael J. Fox Foundation grants Alterity $US495K for Parkinson’s disease research evaluation Strengthening profile at investment, scientific and clinical conferences Dr David Stamler appointed Chief Executive Officer Cash balance as at 31 March 2021 of A$32.8M Alterity Therapeutics Limited (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”) releases its Appendix 4C Quarterly Cash Flow ...

ATH434 protects brain cells and improves motor function

Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”) today announced an oral presentation of expanded animal data to support the commercialisation of its lead compound ATH434 in clinical development for the treatment of Parkinsonian disorders, at the American Academy of Neurology (AAN) virtual annual meeting. The AAN conference, held this week, is the ...

Alterity CEO David Stamler presents to US investors at the HC Wainwright Global Life Science Conference

Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”) CEO Dr David Stamler is presenting to US investors this week as part of the HC Wainwright Global Life Science Conference. The conference held virtually, attracts specialist life science and healthcare investors and features leading companies from around the world. Dr Stamler’s presentation is appended ...

Alterity to present at the 7th International Congress of Multiple System Atrophy

Alterity Therapeutics Limited (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), will present at the upcoming 7th International Congress of Multiple System Atrophy (MSA2021), to be held in a virtual format from February 26-27, 2021. The event is a world leading conference on Multiple System Atrophy (MSA), a rapidly progressive and debilitating neurodegenerative disease without ...

Receive news from Alterity Therapeutics